Related Articles
Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation
Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation
Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report
Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients
Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma‑associated mRNAs in high‑risk neuroblastoma patients